OssDsign AB (publ) (OSSD.ST)
SEK 10.08
(0.4%)
SEK 10.08
(0.4%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 112.15 Million SEK | 96.82% |
| 2022 | 56.98 Million SEK | 79.62% |
| 2021 | 31.72 Million SEK | 27.56% |
| 2020 | 24.87 Million SEK | 47.41% |
| 2019 | 16.87 Million SEK | 27.21% |
| 2018 | 13.26 Million SEK | 72.66% |
| 2017 | 7.68 Million SEK | 83.12% |
| 2016 | 4.19 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 27.02 Million SEK | -22.77% |
| 2024 Q2 | 29.73 Million SEK | 10.02% |
| 2023 Q4 | 34.99 Million SEK | 10.41% |
| 2023 FY | 112.15 Million SEK | 96.82% |
| 2023 Q1 | 21.46 Million SEK | 7.71% |
| 2023 Q2 | 23.99 Million SEK | 11.79% |
| 2023 Q3 | 31.69 Million SEK | 32.09% |
| 2022 Q3 | 17.49 Million SEK | 40.16% |
| 2022 Q2 | 12.48 Million SEK | 76.41% |
| 2022 FY | 56.98 Million SEK | 79.62% |
| 2022 Q4 | 19.93 Million SEK | 13.91% |
| 2022 Q1 | 7.07 Million SEK | -22.87% |
| 2021 FY | 31.72 Million SEK | 27.56% |
| 2021 Q4 | 9.17 Million SEK | 2.82% |
| 2021 Q3 | 8.92 Million SEK | 16.73% |
| 2021 Q2 | 7.64 Million SEK | 27.66% |
| 2021 Q1 | 5.98 Million SEK | -11.43% |
| 2020 Q4 | 6.76 Million SEK | 4.3% |
| 2020 Q3 | 6.48 Million SEK | 65.97% |
| 2020 FY | 24.87 Million SEK | 47.41% |
| 2020 Q1 | 7.72 Million SEK | 52.42% |
| 2020 Q2 | 3.9 Million SEK | -49.46% |
| 2019 Q1 | 3.64 Million SEK | -13.6% |
| 2019 FY | 16.87 Million SEK | 27.21% |
| 2019 Q4 | 5.06 Million SEK | 4.82% |
| 2019 Q3 | 4.83 Million SEK | 40.01% |
| 2019 Q2 | 3.45 Million SEK | -5.27% |
| 2018 Q3 | 3.42 Million SEK | 17.61% |
| 2018 Q2 | 2.9 Million SEK | 9.41% |
| 2018 Q1 | 2.65 Million SEK | 0.0% |
| 2018 FY | 13.26 Million SEK | 72.66% |
| 2018 Q4 | 4.22 Million SEK | 23.39% |
| 2017 FY | 7.68 Million SEK | 83.12% |
| 2016 FY | 4.19 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -1697.1% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 91.831% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 91.831% |
| Arcoma AB | 163.01 Million SEK | 31.198% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 45.018% |
| BICO Group AB (publ) | 2.23 Billion SEK | 94.992% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 80.369% |
| CellaVision AB (publ) | 677.29 Million SEK | 83.44% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -1255.699% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -11388.188% |
| C-Rad AB (publ) | 424.61 Million SEK | 73.586% |
| Duearity AB (publ) | 1.65 Million SEK | -6680.955% |
| Dignitana AB (publ) | 86.06 Million SEK | -30.32% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -988.903% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.648% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -1484.522% |
| Integrum AB (publ) | 104.11 Million SEK | -7.72% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -13022.397% |
| Mentice AB (publ) | 273.61 Million SEK | 59.008% |
| Paxman AB (publ) | 210.11 Million SEK | 46.622% |
| Promimic AB (publ) | 37.07 Million SEK | -202.555% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -45865.984% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -382.499% |
| ScandiDos AB (publ) | 60.42 Million SEK | -85.601% |
| Sectra AB (publ) | 2.96 Billion SEK | 96.216% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 27.108% |
| Senzime AB (publ) | 35.75 Million SEK | -213.691% |
| SpectraCure AB (publ) | 318 Thousand SEK | -35169.497% |
| Stille AB | 294.89 Million SEK | 61.967% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 96.806% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 81.23% |